Jan van de Winkel, PhD
Adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (DRd) reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone (Rd) alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant (ASCT).1
The companies noted that additional data from the trial will be submitted for presentation at a medical conference and publication in a peer-reviewed journal. Genmab and Janssen also intend to communicate with regulatory authorities regarding an indication for the triplet regimen in this setting.
... to read the full story